Indian Pharma Major Receives China Approval; Marks Entry Into Chinese Market

On Friday, the Indian equity benchmarks ended higher, with the benchmark Nifty 50 index closing up 0.27 per cent at 23,719.30. Pharmaceutical stocks remained in focus amid regulatory approvals and global expansion announcements. In this segment, Lupin share price ended marginally lower by 0.12 per cent at Rs 2,281.80 after the company announced approval for Oseltamivir Phosphate Oral Suspension in China.

Lupin Receives China Approval

Lupin Limited announced that China’s National Medical Products Administration has approved its Abbreviated New Drug Application for Oseltamivir Phosphate Oral Suspension in partnership with Yabao Pharmaceuticals, a leading company in China’s paediatric medicine market.

The approval marks Lupin’s first product entry into the Chinese pharmaceutical market, representing a significant milestone in the company’s global expansion strategy.

The approved product, Oseltamivir Phosphate Oral Suspension 6 mg/mL, will be launched for treatment and prevention of influenza A and B, particularly targeting paediatric patients. The medicine is indicated for treatment of influenza in patients aged two weeks and older and for prevention in individuals aged one year and above.

Management Commentary

Fabrice Egros, President - Corporate Development, Lupin, said, “We are delighted that we have received approval for Oseltamivir Oral Suspension in China. This is a strategic step in our entry into one of the world’s largest pharmaceutical markets. It reflects our shared commitment to expanding access to high-quality, affordable therapies, particularly in paediatric care. We look forward to building a stronger presence in this market through our partnership.”

Wei Ren, President, Yabao, said, “We are pleased to announce the official approval of Oseltamivir Oral Suspension in China, marking a key milestone in our partnership with Lupin. It reinforces Yabao’s dedication to quality paediatric medicines and showcases our strong collaboration. We will further expand our R&D portfolio for paediatric and adult chronic disease drugs to jointly advance our businesses.”

About Lupin

Lupin Limited is a global pharmaceutical company headquartered in Mumbai with operations across more than 100 markets. The company operates across branded and generic formulations, biotechnology products, complex generics and active pharmaceutical ingredients.

Lupin has manufacturing facilities and research centres across multiple countries and maintains presence in therapy areas including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal and women’s health.

What are your views on Lupin’s entry into the Chinese pharmaceutical market through this latest approval? Share your thoughts in the comments below.
Disclaimer: This article is for informational purposes only and not investment advice.